Background: The long-term prognosis of patients with hepatocellular carcinoma (HCC) after surgery remains far from satisfactory, especially in patients with microvascular invasion (MVI). This study aimed to evaluate the potential survival benefit from adjuvant lenvatinib for patients with HCC and MVI.

Methods: Patients with HCC after curative hepatectomy were reviewed. All patients were divided into 2 groups according to adjuvant lenvatinib. Propensity score matching (PSM) analysis was used to reduce selection bias and make the results more robust. Survival curves are shown by the Kaplan-Meier (K-M) analysis and compared by the Log-rank test. Univariate and multivariate Cox regression analyses were performed to determine the independent risk factors.

Results: Of 179 patients enrolled in this study, 43 (24%) patients received adjuvant lenvatinib. After PSM analysis, 31 pairs of patients were enrolled for further analysis. Survival analysis before and after PSM analysis showed a better prognosis in the adjuvant lenvatinib group (all P < .05). The adverse events associated with oral lenvatinib were acceptable. Multivariate Cox regression analysis showed that adjuvant lenvatinib was an independent protective factor for improving overall survival (OS) (hazard ratio [HR] = 0.455, 95% confidence interval [CI] = 0.249-0.831, P = .001) and recurrence-free survival (RFS) (HR = 0.523, 95% CI = 0.308-0.886, P = .016).

Conclusions: Postoperative adjuvant targeted therapy can improve the long-term prognosis of patients with HCC and MVI. Therefore, in clinical practice, oral lenvatinib should be recommended for patients with HCC and MVI to decrease tumor recurrence and improve long-term survival.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278397PMC
http://dx.doi.org/10.1177/11795549231180351DOI Listing

Publication Analysis

Top Keywords

adjuvant lenvatinib
24
patients hcc
16
psm analysis
12
patients
11
lenvatinib
8
lenvatinib patients
8
patients hepatocellular
8
hepatocellular carcinoma
8
microvascular invasion
8
curative hepatectomy
8

Similar Publications

Background: Adenoid cystic carcinoma (ACC) is a rare glandular malignancy, commonly originating in salivary glands of the head and neck. Given its protracted growth, ACC is usually diagnosed in advanced stage. Treatment of ACC is limited to surgery and/or adjuvant radiotherapy, which often fails to prevent disease recurrence, and no FDA-approved targeted therapies are currently available.

View Article and Find Full Text PDF

Background: Hepatocellular carcinoma (HCC) with inferior vena cava (IVC) tumor thrombus is generally considered to be borderline resectable because of its poor prognosis. This report describes a patient who underwent multidisciplinary treatment for HCC with massive IVC tumor thrombus.

Methods: The 56-year-old woman in this study had diffuse HCC of the medial and anterior segments.

View Article and Find Full Text PDF

Background: Intrahepatic cholangiocarcinoma is a malignant tumor that starts from the epithelium of the bile duct and has a poor prognosis. They are characterized by poor response to chemotherapy and lack of effective targeted therapies; thus, therapeutic options are limited.

Case Presentation: A 59-year-old man was admitted to the hospital for a workup of abnormal CA19-9 levels.

View Article and Find Full Text PDF

Systemic Therapy for Hepatocellular Carcinoma.

Clin Liver Dis

February 2025

Department of Medicine, Division of Medical Oncology, Duke University Health System, Durham, NC, USA. Electronic address:

Systemic therapy for hepatocellular carcinoma has evolved from sorafenib to now include immune checkpoint blockade, either atezolizumab/bevacizumab or durvalumab/tremelimumab, and soon to include camrelizumab/rivoceranib and nivolumab/ipilimumab. Second-line therapy remains predominantly either a multikinase inhibitor or ramucirumab. Areas of development include testing immune checkpoint-based regimens in the adjuvant setting after surgery, ablation, or transarterial embolization.

View Article and Find Full Text PDF
Article Synopsis
  • The study compared the combination of lenvatinib and pembrolizumab (len + pembro) with traditional chemotherapy for advanced or recurrent endometrial cancer (aEC) in patients who had not previously been treated.
  • Results showed that while len + pembro did not statistically outperform chemotherapy in terms of progression-free survival (PFS) or overall survival (OS), it offered similar outcomes, indicating noninferiority.
  • The trial involved 842 patients and found median PFS and OS were comparable between the two treatment groups, suggesting len + pembro could be an effective alternative to chemotherapy for this cancer type.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!